ArticleCurrent treatment options in neurology2002
Peripheral Neuropathy Due to Leprosy.
Article in Current treatment options in neurology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- The armadillo: a model for the neuropathy of leprosy and potentially other neurodegenerative diseases.Disease models & mechanisms · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leprosy, also known as Hansen's disease, remains a significant cause of disability worldwide. After the introduction of treatment regimens using a combination of dapsone, rifampin, and clofazimine, the prevalence of the disease declined from 5.4 million registered cases in 1985 to less than a million in 1999. However, the incidence of new cases has remained stable due at least in part to a population of asymptomatic carriers. Immune-mediated nerve damage can occur during treatment or after treatment is completed and mandates continued careful follow-up of patients. Patient education and rehabilitation are crucial aspects of disease management and prevention of disability. In the US, patient care and medications are available through regional clinics sponsored by the Department of Health and Human Services. Patients should contact the National Hansen's Disease Program at 1770 Physician's Park Drive, Baton Rouge, Louisiana 70816; 1-800-642-2477.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.